Comparison of Clinical Features in HLA-B27 Positive and Negative Patients With Axial Spondyloarthritis: Results From a Cohort of 4,131 Patients

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2021 Jan 11

PMID 33425955

Citations 11

Authors

Shangzhu Zhang

Yanhong Wang

Linyi Peng

Jinmei Su

Xiaofeng Zeng

Mengtao Li

Zhenbiao Wu

Jian Xu

Min Yang

Lijun Wu

Cheng Zhao

Xinwang Duan

Qin Li

Jing Zhu

Wenqiang Fan

Affiliations

Soon will be listed here.

Abstract

The aim of our study was to assess the influence of the HLA-B27 status on axial spondyloarthritis (axSpA) in the largest cohort in China. An observational, cross-sectional, and analytic study of axSpA patients from the China axSpA database was performed. Demographic and clinical data were compared in terms of the HLA-B27 status. Univariate and multivariate analyses were performed to identify variables related to HLA-B27 presence. We enrolled 4,131 patients in this study; of those, 36,95 (89.4%) were HLA-B27 positive. In the multivariate analysis, male gender ( < 0.001), younger age ( < 0.001), a disease duration of more than 3 years ( < 0.001), a family history of SpA ( < 0.001), uveitis ( < 0.001), ASDAS-CRP ( < 0.001), and biologic treatment ( < 0.001) were the main variables that were independently related to HLA-B27 presence, whereas a diagnosis delay time >36 months ( < 0.001) and psoriasis ( < 0.001) were independently related to HLA-B27 absence. In Chinese axial SpA patients, presence of HLA-B27 is associated with the male sex, younger age, longer disease duration, greater family aggregation, and higher frequency of uveitis; absence of HLA-B27 is associated with longer diagnosis delay time and higher frequency of psoriasis.

Citing Articles

Association of Endoplasmic Reticulum Aminopeptidase 1 Gene Polymorphism with Susceptibility and Severity of Axial Spondyloarthritis in Egyptian Population: A Single-center Case-Control Study.

Saad M, Abdul-Sattar A, Abdelal I, Barak A Ann Afr Med. 2024; 23(3):443-451.

PMID: 39034571 PMC: 11364326. DOI: 10.4103/aam.aam_180_23.

Alarming serum antiprotease levels in axial spondyloarthritis.

Kul A, Tuzun Z, Celik M Arch Rheumatol. 2024; 39(2):285-293.

PMID: 38933721 PMC: 11196224. DOI: 10.46497/ArchRheumatol.2024.10466.

Exploring the Pathogenesis of Spondylarthritis beyond HLA-B27: A Descriptive Review.

Nagit R, Rezus E, Cianga P Int J Mol Sci. 2024; 25(11).

PMID: 38892265 PMC: 11172491. DOI: 10.3390/ijms25116081.

How to translate genetic findings into clinical applications in spondyloarthritis?.

Frison E, Breban M, Costantino F Front Immunol. 2024; 15:1301735.

PMID: 38327520 PMC: 10847566. DOI: 10.3389/fimmu.2024.1301735.

Clinical profile and treatment utilisation based on HLA-B*27 status in axial spondyloarthritis: results from ASAS-PerSpA study.

Chaudhary H, Lopez-Medina C, Khan M, Dougados M, Magrey M RMD Open. 2023; 9(3).

PMID: 37491128 PMC: 10373694. DOI: 10.1136/rmdopen-2023-003179.

References

Pascual E, Fontanilla Ortega P, Vicens Bernabeu E, Martinez-Costa L, Blanco Alonso R . Clinical characteristics, treatment and ocular complications of HLA-B27-related anterior uveitis and HLA-B27-non related anterior uveitis. Reumatol Clin. 2015; 12(5):244-7. DOI: 10.1016/j.reuma.2015.11.008. View

Nazarinia M, Ghaffarpasand F, Heiran H, Habibagahi Z . Pattern of ankylosing spondylitis in an Iranian population of 98 patients. Mod Rheumatol. 2009; 19(3):309-15. DOI: 10.1007/s10165-009-0153-5. View

Kim T, Na K, Lee H, Lee B, Kim T . HLA-B27 homozygosity has no influence on clinical manifestations and functional disability in ankylosing spondylitis. Clin Exp Rheumatol. 2009; 27(4):574-9. View

DAmbrosio E, La Cava M, Tortorella P, Gharbiya M, Campanella M, Iannetti L . Clinical Features and Complications of the HLA-B27-associated Acute Anterior Uveitis: A Metanalysis. Semin Ophthalmol. 2016; 32(6):689-701. DOI: 10.3109/08820538.2016.1170158. View

Jaakkola E, Herzberg I, Laiho K, Barnardo M, Pointon J, Kauppi M . Finnish HLA studies confirm the increased risk conferred by HLA-B27 homozygosity in ankylosing spondylitis. Ann Rheum Dis. 2005; 65(6):775-80. PMC: 1798178. DOI: 10.1136/ard.2005.041103. View

Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C . Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?. Arthritis Care Res (Hoboken). 2012; 64(9):1415-22. DOI: 10.1002/acr.21688. View

Garrett S, Jenkinson T, Kennedy L, Whitelock H, Gaisford P, Calin A . A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994; 21(12):2286-91. View

Sheehan N . HLA-B27: what's new?. Rheumatology (Oxford). 2010; 49(4):621-31. DOI: 10.1093/rheumatology/kep450. View

Rudwaleit M, Claudepierre P, Wordsworth P, Loza Cortina E, Sieper J, Kron M . Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol. 2009; 36(4):801-8. DOI: 10.3899/jrheum.081048. View

10.

Marzo-Ortega H, McGonagle D, OConnor P, Hensor E, Bennett A, Green M . Baseline and 1-year magnetic resonance imaging of the sacroiliac joint and lumbar spine in very early inflammatory back pain. Relationship between symptoms, HLA-B27 and disease extent and persistence. Ann Rheum Dis. 2008; 68(11):1721-7. DOI: 10.1136/ard.2008.097931. View

11.

Gladman D, Rahman P, Cook R, Shen H, Zummer M, Thomson G . The Spondyloarthritis Research Consortium of Canada registry for spondyloarthritis. J Rheumatol. 2011; 38(7):1343-8. DOI: 10.3899/jrheum.101102. View

12.

Chung H, Machado P, van der Heijde D, DAgostino M, Dougados M . HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging: results from the DESIR cohort of patients with recent onset axial spondyloarthritis. Ann Rheum Dis. 2011; 70(11):1930-6. DOI: 10.1136/ard.2011.152975. View

13.

Feldtkeller E, Khan M, van der Heijde D, van der Linden S, Braun J . Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int. 2003; 23(2):61-6. DOI: 10.1007/s00296-002-0237-4. View

14.

Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewe R, van ver Tempel H, Mielants H . Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis. 2003; 62(2):127-32. PMC: 1754445. DOI: 10.1136/ard.62.2.127. View

15.

Sampaio-Barros P, Bertolo M, Kraemer M, Neto J, Samara A . Primary ankylosing spondylitis: patterns of disease in a Brazilian population of 147 patients. J Rheumatol. 2001; 28(3):560-5. View

16.

Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J . Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2008; 68(1):18-24. DOI: 10.1136/ard.2008.094870. View

17.

Sampaio-Barros P, Conde R, Bonfiglioli R, Bertolo M, Samara A . Characterization and outcome of uveitis in 350 patients with spondyloarthropathies. Rheumatol Int. 2006; 26(12):1143-6. DOI: 10.1007/s00296-006-0203-7. View

18.

Cortes A, Hadler J, Pointon J, Robinson P, Karaderi T, Leo P . Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet. 2013; 45(7):730-8. PMC: 3757343. DOI: 10.1038/ng.2667. View

19.

Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J . The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009; 68(6):777-83. DOI: 10.1136/ard.2009.108233. View

20.

Ruiz D, de Azevedo M, Lupi O . HLA-B27 frequency in a group of patients with psoriatic arthritis. An Bras Dermatol. 2012; 87(6):847-50. PMC: 3699907. DOI: 10.1590/s0365-05962012000600004. View